Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis

Exclusion Criteria

• •Recurrent vulvovaginal candidiasis(4 episodes of VVC in the last 12 months).
• •Women with other cause of vaginal infections, e.g. bacterial vaginosis, aerobic vaginitis, trichomoniasis, and mixed infections
• •Women using oral or vaginal antifungals within 2 weeks prior to enrolment and during the study.
• •Women using any intra-vaginal products, also vaginal douches containing soaps and other anionic, surface-active substances, within 2 weeks prior to enrolment and during the study.
• •Women using any antibiotic or anti-infective within 2 weeks prior to enrolment.
• •Cervicitis, abnormal PAP smear in the last 6 month.
• •Severe systemic diseases (HIV infection, diabetes mellitus, cancer, tuberculosis, autoimmune diseases, severe psychiatric conditions, etc.).
• •Women with confirmed Neisseria gonorrhoea or Chlamydia trachomatis.
• •Women having menstruation bleeding at enrolment.
• •Known or suspected hypersensitivity to one of the study medications, inclusive their excipients.
• •Participation of patient in another investigational drug study concomitantly or within 30 days prior to entry in the study.
• •Patient is relative of, or staff directly reporting to, the investigator.